For the Inventor, By the Inventor

Enter inventor name

San Jose, CA, United States of America

John A Lewicki

USPTO Granted Patents = 52 (Patent Applications = 8)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 3.8

ph-index = 22

Forward Citations = 1,370(Granted Patents)

Forward Citations (Not Self Cited) = 1,297(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Sunnyvale, CA (US) (1985 - 1993)
San Jose, CA (US) (1984 - 2007)
Los Gatos, CA (US) (1990 - 2017)

Company Filing History:

Oncomed Pharmaceuticals, Inc.

California Biotechnology Inc.

Biotechnology Research Associates, J.v.

Scios Nova, Inc.

7. 1 out of 5,309

Leland Stanford Junior University

8. 1 out of 3,381

University of Michigan

where one patent can have more than one assignee

Years Active: 1984-2017

Loading Chart...

Loading Chart...

Areas of Expertise:

Cancer Treatment

NOTCH Receptors

Monoclonal Antibodies

Wnt Signaling

Natriuretic Peptides

Lactobacilli Polypeptides

Quinazoline Derivatives

Biologically Active Proteins

Cardiac Failure

Immunoassays

Polynucleotides

Tumor Cell Growth

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9850311 - Compositions and methods for diagnosing and treating cancer (2017-12-26),

2. 9732139 - Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor (2017-08-15),

3. 9676865 - Antibodies to a non-ligand binding region of at least two NOTCH receptors (2017-06-13),

4. 9505832 - Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3 (2016-11-29),

5. 9228013 - Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell (2016-01-05),

6. 8980260 - Monoclonal antibody that binds human notch2 and notch3 (2015-03-17),

7. 8945873 - Polynucleotides encoding Notch receptor antibodies (2015-02-03),

8. 8784811 - Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1 (2014-07-22),

9. 8765913 - Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells (2014-07-01),

10. 8652472 - Compositions and methods for diagnosing and treating cancer (2014-02-18),

11. 8425903 - Methods of treatment by administering antibodies to notch receptors (2013-04-23),

12. 8404237 - Antibodies to the NOTCH1 receptor (2013-03-26),

13. 8324361 - Nucleic acid molecules encoding soluble frizzled (FZD) receptors (2012-12-04),

14. 8226943 - Antibodies to notch receptors (2012-07-24),

15. 8206713 - Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2 (2012-06-26),

Title: The Innovative Journey of John A Lewicki

Introduction: John A Lewicki, a visionary inventor based in San Jose, CA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: John A Lewicki holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his commitment to pushing the boundaries of innovation.

Career Highlights: With a career spanning over two decades, John A Lewicki has worked with leading tech companies in Silicon Valley, where he has played a key role in developing cutting-edge technologies that have revolutionized various industries.

Collaborations: Throughout his career, John A Lewicki has collaborated with top researchers, engineers, and scientists to bring his innovative ideas to life. His collaborative spirit has led to the successful implementation of groundbreaking technologies.

Conclusion: John A Lewicki's passion for innovation and his relentless pursuit of technological advancement have solidified his position as a prominent figure in the world of inventors. His contributions continue to inspire future generations of innovators to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…